Novel strategies are required to move from simply controlling multiple myeloma (MM), to overcoming it and acheiving long-term remissions in the majority of patients. Here, Gareth Morgan, MD, PhD, FRCP, FRCPath, of the University of Arkansas for Medical Sciences, Little Rock, AR, discusses how we can design new strategies for unprecedented outcomes in MM. Dr Morgan discusses 'synergistic casettes' of treatment, that could be switched and used to overcome resistance. He also highlights other immuno-oncology agents, including IMiDs, CAR T-cells, bispecific antibodies and antibody-drug conjugates. Dr Morgan highlights the need for new endpoints in trials, in order to find improved treatments that are clinically-meaningful, allowing patients to acheive deep responses. Another complexity is the heterogeneity of MM, which will require innovative diagnostics and treatment designs to target the different subtypes. This interview was recorded at the 23rd congress of European Hematology Association (EHA) 2018, held in Stockholm, Sweden.